Background/Aims: Pendrin (SLC26A4), a transporter accomplishing anion exchange, is expressed in inner ear, thyroid gland, kidneys, lung, liver and heart. Loss or reduction of function mutations of SLC26A4 underlie Pendred syndrome, a disorder invariably leading to hearing loss with enlarged vestibular aqueducts and in some patients to hypothyroidism and goiter. Renal pendrin expression is up-regulated by mineralocorticoids such as aldosterone or deoxycorticosterone (DOCA). Little is known about the impact of mineralocorticoids on pendrin expression in extrarenal tissues. Methods: The present study utilized RT-qPCR and Western blotting to quantify the transcript levels and protein abundance of Slc26a4 in murine kidney, thyroid, heart and lung prior to and following subcutaneous administration of 100 mg/kg DOCA. Results: Slc26a4 transcript levels as compared to Gapdh transcript levels were significantly increased by DOCA treatment in kidney, heart, lung and thyroid. Accordingly pendrin protein expression was again significantly increased by DOCA treatment in kidney, heart, lung and thyroid. Conclusion: The observations reveal mineralocorticoid sensitivity of pendrin expression in kidney, heart, thyroid and lung.
DOCA Sensitive Pendrin Expression in

Introduction
Pendrin is an electroneutral anion exchanger transporting chloride, bicarbonate, iodide and further anions [1] [2] [3] . Loss or reduction of function mutations in the pendrin gene A. Arithmetic means ± SEM (n = 5) of Slc26a4 mRNA abundance in kidney from animals without treatment (white bar) and 3 hours following subcutaneous injection of 100 mg/kg DOCA (black bar). **(p<0.01) indicates statistically significant difference with respect to untreated animals. B. Dose response curve of DOCA induced up-regulation of Slc26a4 mRNA levels. *(p<0.05) indicates statistically significant difference to untreated animals. C. Representative original blot for pendrin protein abundance in kidney from animals without treatment (-DOCA) and 3 hours following subcutaneous injection of 100 mg/kg DOCA (+DOCA). D. Arithmetic means ± SEM (n = 5) of Slc26a4 protein abundance in kidney from animals without treatment (white bar) and 3 hours following subcutaneous injection of 100 mg/kg DOCA (black bar). ***(p<0.001) indicates statistically significant difference to untreated animals.
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Results
Semi-quantitative reverse transcription polymerase chain reaction (RT-qPCR) was employed to quantify the transcript levels encoding Slc26a4 and Western blotting was utilized to quantify the Slc26a4 protein abundance in murine kidney, thyroid, heart and lung prior to and following subcutaneous administration of 20, 50 or 100 mg/kg DOCA.
As illustrated in Fig. 1A ,B, the abundance of Slc26a4 mRNA in the kidney was significantly increased following treatment of mice with the deoxycorticosterone DOCA (100 mg/kg). Normalization of the Slc26a4 transcript levels to the transcript levels of the house keeping gene Gapdh yielded the Slc26a4/Gapdh transcript level ratio, which was significantly increased by DOCA treatment (by 160%, n = 5). The increase of Slc26a4 transcript levels following DOCA treatment was paralleled by an increase of Slc26a4 protein abundance (Fig.  1C and Fig. 1D) .
Similar to what was observed in the kidney, DOCA (50 or 100 mg/kg) treatment significantly increased Slc26a4 transcript levels in the heart ( Fig. 2A,B) . The increase of the cardiac Slc26a4 transcript levels following DOCA treatment was similarly evidenced by an increase of the Slc26a4/Gapdh transcript level ratio in the heart (by 160%, n = 9). The increase of cardiac Slc26a4 transcript levels following DOCA treatment was similarly paralleled by an increase of cardiac SLC26A4 protein abundance (Fig. 2C and Fig. 2D ).
As illustrated in Fig. 3A ,B, both, Slc26a4 mRNA and protein were expressed in the lung. Similar to what was observed in kidney and heart, the mineralocorticoid treatment (DOCA 50 or 100 mg/kg) significantly increased lung Slc26a4 transcript levels. The increase of Fig. 2 . Slc26a4 mRNA and protein abundance in heart without and with DOCA treatment. A. Arithmetic means ± SEM (n = 9) of Slc26a4 mRNA abundance in heart from animals without treatment (white bar) and 3 hours following subcutaneous injection of 100 mg/kg DOCA (black bar). **(p<0.01) indicates statistically significant difference to untreated animals. B. Dose response curve of DOCA induced up-regulation of Slc26a4 mRNA levels. *(p<0.05), **(p<0.01) indicates statistically significant difference to untreated animals. C. Representative original blot for pendrin protein abundance in heart from animals without treatment (-DOCA) and 3 hours following subcutaneous injection of 100 mg/kg DOCA (+DOCA). D. Arithmetic means ± SEM (n = 5) of SLC26A4 protein abundance in heart from animals without treatment (white bar) and 3 hours following subcutaneous injection of 100 mg/kg DOCA (black bar). *(p<0.05) indicates statistically significant difference to untreated animals.
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Slc26a4 transcript levels following DOCA treatment was again evidenced by an increase of Slc26a4/Gapdh transcript level ratio (by 153%, n = 9). The increase of Slc26a4 transcript levels following DOCA treatment was again paralleled by an increase of Slc26a4 protein abundance ( Fig. 3C and Fig. 3D ). Lastly, DOCA (50 or 100 mg/kg) treatment increased Slc26a4 transcript levels in thyroid gland (Fig. 4A,B) . The increase of the thyroid Slc26a4 transcript levels following DOCA treatment was again evidenced by an increase of the Slc26a4/Gapdh transcript level ratio (by 319%, n = 7). The increase of thyroid Slc26a4 transcript levels following DOCA treatment was again paralleled by an increase of thyroid Slc26a4 protein abundance (Fig. 4C and Fig.  4D ).
Discussion
The present study demonstrates that pendrin transcript (Slc26a4) levels and pendrin protein abundance in kidney, heart, lung and thyroids are modified by the mineralocorticoid deoxycorticosterone (DOCA).
The present study did not attempt to define the molecular mechanisms involved in the up-regulation of the carrier. A candidate signaling molecule is the serum & glucocorticoid inducible kinase SGK1, which is strongly upregulated by mineralocorticoids and is a powerful regulator of a variety of channels and transporters [68] . SGK1 is partially effective by upregulating the transcription factor NFκB [69] , which contributes to the stimulating effect of [70] . Whether or not NFκB is involved in the up-regulation of SLC26A4 expression during mineralocorticoid excess or inflammation, remains to be tested. The effect of DOCA on SLC26A4 expression in the kidney is expected to affect HCO 3 -secretion and Cl -reabsorption across the distal nephron [17, [25] [26] [27] [28] . Moreover, SLC26A4 is expected to modify expression and function of the renal epithelial Na + channel ENaC resulting in enhanced renal tubular NaCl transport and increased blood pressure [28] [29] [30] [31] [32] [33] . As a matter of fact, pendrin deficient mice are resistant to aldosterone-induced hypertension [32] .
The up-regulation of SLC26A4 expression in lung tissue may serve to foster transport of anions across the aiway epithelium [23, 24] . Notably, SLC26A4 expression is up-regulated in bronchial asthma and chronic obstructive pulmonary disease. The carrier presumably does play an active role in respiratory inflammation and tissue destruction/remodeling [23, 24] .
The effect of DOCA treatment on SLC26A4 protein abundance is only moderate in lung tissue. Nevertheless, the effect is statistically significant. Possibly, mineralocorticoids upregulate SLC26A4 protein abundance only in a subset of cells in lung tissue. If so, Western blotting of whole organ tissue would underestimate the effect on mineralocorticoid sensitive cells.
The functional role of pendrin sensitivity to DOCA in other tissues is less obvious. In theory, the up-regulation of pendrin in the thyroid could impact on the formation of thyroid hormones. Loss of function SLC26A4 mutations, however, do not necessarily affect iodide transport and hormone release in thyroid glands [12, 14, 20, 21] . Thus, aldosterone sensitive regulation of SLC26A4 in the thyroid may be relevant for functions other than thyroid hormone release. It is worth mentioning, however, that the heart has been claimed to possess all enzymes required for thyroid hormone formation [16] . SLC26A4 is further known to serve cell volume regulation [22] . Parallel activation of Na + /H + exchangers and Cl -/HCO 3 -exchangers participate in cell volume increase [71, 72] , as they accomplish cellular NaCl uptake, which in turn is followed by osmotically driven water entry. [73] [74] [75] [76] [77] [78] [79] [80] , heart [81] [82] [83] [84] [85] , and a variety of other extrarenal tissues [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] .
Opposite regulation of SLC26A4 activity and expression have previously been observed in liver and kidney following alterations of acid base balance [15] . Following acidosis Slc26a4 transcript levels, protein abundance and/or activity are down-regulated in kidney [15, 27, 67, 104] and Slc26a4 transcript levels are up-regulated in liver [15] . Similarly, carbonic anhydrase inhibition or deficiency downregulate Slc26a4 expression in the kidney [15, 105, 106] but up-regulate Slc26a4 transcript levels in liver [15] . Conversely, bicarbonate induced metabolic alkalosis up-regulates Slc26a4 expression in the kidney [15, 105] , but down-regulates Slc26a4 transcript levels in liver [15] . The opposite regulation of pendrin in liver and kidney may serve the complimentary functions of these organs in the regulation of systemic acid-base balance [107] . As mineralocorticoids stimulate renal tubular H + secretion and thus cause alkalosis [27] , their effect on renal pendrin may similarly aim to influence acid base balance.
In conclusion, Slc26a4 transcripts and protein were observed in kidney, thyroids, lung and heart. Moreover, SLC26A4 abundance was sensitive to DOCA not only in kidney, but as well in heart, thyroids and lung. The present observation point to DOCA sensitive pendrin functions beyond its well established role in inner ear, thyroids and kidney. 
